Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teriflunomide
Drug ID BADD_D02165
Description Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Indications and Usage Used in the treatment of relapsing forms of multiple sclerosis (MS).
Marketing Status Prescription
ATC Code L04AA31
DrugBank ID DB08880
KEGG ID D10172
MeSH ID C527525
PubChem ID 54684141
TTD Drug ID Not Available
NDC Product Code 69238-1303; 65727-058; 12579-186; 69238-1304; 66499-0059; 59285-001; 69539-032; 47621-049; 17337-0070; 69037-0016; 58468-0211; 63850-8081; 12579-185; 46708-888; 12579-191; 53747-061; 69539-033; 14501-0086; 58468-0210; 59651-036; 66039-916; 0115-1565; 12579-190
Synonyms teriflunomide | (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide | 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide | RS 61980 | Aubagio | HMR1726 | HMR-1726 | A 771726 | A 1726 | A771726 | A-771726 | A77 1726
Chemical Information
Molecular Formula C12H9F3N2O2
CAS Registry Number 163451-81-8
SMILES CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety19.06.02.002--
Aphasia19.21.01.001; 17.02.03.001--
Aphonia22.02.05.024; 19.19.01.002; 17.02.08.0090.002895%
Aphthous ulcer07.05.06.0020.003474%Not Available
Appendicitis11.01.07.001; 07.19.01.0010.005211%
Arrhythmia02.03.02.001--Not Available
Arteriospasm coronary24.04.04.005; 02.02.02.0050.001158%Not Available
Arthralgia15.01.02.0010.030108%
Arthritis15.01.01.001--
Arthropathy15.01.01.0030.005790%Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.0060.017370%
Aspiration22.02.07.0070.001158%
Asthenia08.01.01.0010.042266%Not Available
Asthma22.03.01.002; 10.01.03.0100.006369%Not Available
Ataxia17.02.02.001; 08.01.02.0040.004053%
Atrial fibrillation02.03.03.002--
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.002316%Not Available
B-cell lymphoma16.28.01.001; 01.15.01.0010.000906%Not Available
Back disorder15.03.01.014--Not Available
Back pain15.03.04.0050.019686%
Basal cell carcinoma23.08.02.001; 16.03.02.0010.001737%Not Available
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.0030.004053%Not Available
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Bladder pain20.02.02.001--Not Available
Blepharospasm17.17.02.001; 06.05.01.0010.001737%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness transient17.17.01.004; 06.02.02.0020.001158%Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.002895%Not Available
Blister23.03.01.001; 12.01.06.0020.013317%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 26 Pages